The core directed by Drs. de Silva and Miley will provide the following services. 1) Cloning of recombinant dengue protein "constructs for expression (Aim 1 Miley) 2) Cloning of recombinant influenza protein constructs for expression (Aim 1 Miley) 3) Large scale production and purification of dengue antigens from the 4 serotypes (Aim 1 Miley) 4) Large scale production and purification of influenza antigens (Aim 1 Miley) 5) Assessing the structural integrity of recombinant antigens (Aim 1- desilva) 6) Quality control testing of vaccine antigens (Aim 1-Miley) 7) Growth of hybridomas and purification of monoclonal antibodies (Aim 2-Miley) 8) Testing of immune sera for DENV neutralizing antibodies against the 4 serotypes (Aim 3 desilva) 9) Testing the breadth of neutralizing antibody responses using panels of viruses that cover the genetic diversity of each dengue serotype (Aim 3 deSilva)

Public Health Relevance

Dengue is the most significant arboviral infection of humans. Currently there are no vaccines or drugs against this virus. The overall objective of this program is to combine a unique nanoparticle production process with novel innate immune regulators to develop a broad spectrum platform for delivering vaccines against dengue and influenza viruses. This core will provide specific reagents and assays required for developing and evaluating dengue virus vaccines.

Agency
National Institute of Health (NIH)
Type
Research Program--Cooperative Agreements (U19)
Project #
1U19AI109784-01
Application #
8657217
Study Section
Special Emphasis Panel (ZAI1)
Project Start
Project End
Budget Start
Budget End
Support Year
1
Fiscal Year
2014
Total Cost
Indirect Cost
Name
University of North Carolina Chapel Hill
Department
Type
DUNS #
City
Chapel Hill
State
NC
Country
United States
Zip Code
27599